Core Insights - Edelman Financial Engines has transitioned its technology stack to Orion, moving away from Envestnet, which it had used since 2018 [2][4] - This shift is significant for Orion, as Edelman is one of the largest registered investment advisors (RIAs) in the U.S. with over $308 billion in assets under management [1][3] - The change in technology providers comes amid leadership transitions at Edelman, including a new CEO and recent departures of key executives [4][5] Group 1: Company Transition - Edelman has fully onboarded its advisors to Orion's platform, which includes portfolio management, trading, data sharing, and advisor engagement tools [2][6] - The transition to Orion is expected to enhance the integration of systems and improve the tools available to planners, ultimately benefiting client experience [4][6] Group 2: Leadership Changes - Ralph Haberli has recently taken over as CEO of Edelman, succeeding Jay Shah, and has a background from Capital Group [4][5] - The firm has also seen the departure of its Chief Financial Officer and Chief Compliance Officer, indicating ongoing changes in its leadership structure [5] Group 3: Market Position - Orion manages approximately $5.8 trillion in assets under administration, while its competitor Envestnet manages around $7 trillion [3][6] - Edelman is majority-owned by Hellman & Friedman and has a minority stake from Warburg Pincus, with founder Ric Edelman being the largest individual shareholder [7]

Core Viewpoint - Orion Energy Systems, Inc. will host a conference call and webcast to discuss its fiscal 2026 third quarter results on February 5, 2026, at 10:00 a.m. ET, with results being released prior to market opening on the same day [1]. Group 1: Conference Call and Webcast Details - The conference call is scheduled for Thursday, February 5, 2026, at 10:00 a.m. ET [2]. - Participants must pre-register to receive dial-in information through the provided registration link [2]. - A webcast and replay of the call will be available at a specified URL [2]. Group 2: Company Overview - Orion Energy Systems specializes in energy-efficient LED lighting, EV charging solutions, and electrical maintenance services [3]. - The company focuses on turnkey design-through-installation solutions for large national customers and projects through ESCO and distribution partners [3]. - Orion aims to help customers achieve their business, financial, and environmental goals with high-quality, innovative solutions and reliable customer service [3]. Group 3: Sustainability Commitment - Orion is dedicated to operating responsibly across all areas of its organization, emphasizing sustainability and governance priorities [4].

Revenue Outlook - Orion Energy Systems, Inc. announced expected quarterly revenue results for Q4 fiscal 2026, ending December 31, 2025[6] - The company provided an updated revenue outlook for fiscal 2026, indicating growth expectations[6] - Guidance for fiscal 2027 revenue was also included in the announcement, suggesting continued positive momentum[6]

Core Insights - Orion Energy Systems, Inc. has increased its FY 2026 revenue guidance to a range of $84 million to $86 million, up from a previous estimate of approximately $84 million, and anticipates positive net income in FY26 Q3 with expected revenue of around $21 million [3][4] - The company has secured a new large-scale LED exterior lighting project with a leading international retail chain, expected to generate approximately $14 million to $15 million in revenue, starting in FY26 Q4 [1][2] - Orion expects to achieve positive adjusted EBITDA on revenue between $95 million and $97 million in FY 2027, attributing growth to increased orders from enterprise customers and recent cost-structure improvements [4] Revenue and Contracts - The new LED exterior lighting project follows a three-year renewal of a major LED lighting maintenance contract with the same enterprise customer, valued between $42 million and $45 million, covering maintenance for over 2,000 stores [2] - The company has achieved positive adjusted EBITDA for five consecutive quarters and expects to maintain this trend for the full FY 2026 [3] Future Outlook - Orion's heightened expectations for growth and profitability are linked to increasing orders from enterprise customers and improvements in its cost structure [4] - The company is focused on expanding its scope of work with large enterprise customers, indicating potential for further revenue growth [3]

Core Insights - Bayer AG's shares rose by 6.6% following Orion's projection that long-term annual net sales from Nubeqa could exceed €1 billion, based on collaborative scenario planning [1][7] Group 1: Product Performance and Strategic Priorities - Nubeqa, developed jointly by Bayer and Orion, is approved for various prostate cancer indications in the U.S. [2] - Bayer outlined its strategic priorities for the Pharmaceuticals Division at the J.P. Morgan Healthcare Conference, emphasizing the strong performance of Nubeqa and Kerendia, which are offsetting declining sales of Xarelto [3][4] - Bayer's stock surged 126% over the past year, significantly outperforming the industry growth of 22.7% [4] Group 2: Future Growth Drivers - Bayer is focusing on new drug launches such as Beyonttra, Lynkuet, and asundexian to drive future growth [5][7] - Kerendia received FDA approval for expanded use in heart failure patients, becoming the only non-steroidal mineralocorticoid receptor antagonist approved for chronic kidney disease associated with type 2 diabetes [8] - Asundexian, an investigational oral Factor XIa inhibitor, has shown promising results in late-stage studies and is viewed as a potential blockbuster opportunity [10] Group 3: Oncology and Women's Health Developments - Nubeqa continues to show strong global uptake, with additional phase III readouts expected to extend its use [14] - The FDA approved elinzanetant for menopause-related symptoms, marking a significant boost for Bayer's women's health portfolio [17] - Bayer's pipeline includes advancements in cell therapy and gene therapy, with ongoing developments in treatments for Parkinson's disease and late-onset Pompe disease [18][19] Group 4: Overall Business Outlook - Bayer's pharmaceutical business is entering a new growth phase, supported by key revenue drivers, multiple late-stage catalysts, and a robust pipeline [20]

Core Insights - The company aims to identify an initial platform acquisition that aligns with its service offerings and requires minimal changes to the tech stack [2] - The firm adopts a CRM-centric approach, utilizing Salesforce as a central hub for client relationship management, integrating various systems for streamlined operations [3] - The company employs Orion for portfolio management and reporting, benefiting from its robust platform and strategic acquisitions [4][6] - The firm invests in both organic growth and inorganic acquisitions, emphasizing the importance of flexible systems for continuity during integration [5] - Microsoft is chosen for document management and office productivity to ensure compatibility with advisory practices joining the firm, avoiding complications associated with different document editors [7]

Core Viewpoint - The article emphasizes the importance of identifying and maintaining stock price trends for successful short-term investing, highlighting the use of a specific screening strategy to find stocks with strong fundamentals and positive momentum. Group 1: Stock Screening Strategy - The "Recent Price Strength" screen is designed to identify stocks with sufficient fundamental strength to sustain their recent upward trends, focusing on those trading in the upper portion of their 52-week high-low range, indicating bullishness [3]. - Orion Energy Systems, Inc. (OESX) is highlighted as a candidate that passed the screening, showing a significant price increase of 76.7% over the past 12 weeks, reflecting investor confidence in its potential upside [4]. - OESX has also maintained a price increase of 13% over the last four weeks, indicating that the upward trend is still intact, and it is currently trading at 85% of its 52-week high-low range, suggesting a potential breakout [5]. Group 2: Fundamental Strength - OESX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The Zacks Rank system has a strong historical performance, with Rank 1 stocks generating an average annual return of +25% since 1988, indicating the reliability of this ranking system [7]. - The Average Broker Recommendation for OESX is also 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Additional Insights - Besides OESX, there are other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities for trend-focused investors [8]. - The article encourages investors to explore various Zacks Premium Screens tailored to different investing styles, which can help identify winning stock picks [8].

Core Insights - Orion anticipates significant growth for darolutamide, a prostate cancer medication co-developed with Bayer [1] Company Summary - Orion is focused on the development and commercialization of darolutamide, indicating a strong commitment to the oncology market [1] Industry Summary - The prostate cancer treatment market is expected to expand, with darolutamide positioned as a key player due to its co-development with Bayer [1]

ORION CORPORATION STOCK EXCHANGE RELEASE 14 JANUARY 2026 at 16:00 EET Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion As the company announced earlier today on 14 January 2026, the Nubeqa® product has become Orion's largest product by far, and its financial significance for the company will increase further. For this reason, Orion decided to provide an estimate of the net sales potential of Nubeqa®. As noted earlier, based on scenario planning with p ...

Group 1: Company Overview - Legence (LGN) is part of the Construction sector, which includes 93 individual stocks and currently holds a Zacks Sector Rank of 16, indicating its relative strength within the sector [2] - Legence has a Zacks Rank of 2 (Buy), reflecting a positive earnings outlook, with the consensus estimate for full-year earnings having increased by 28.1% over the past quarter [3] Group 2: Performance Analysis - Year-to-date, Legence has gained approximately 6.9%, outperforming the average gain of 5.5% for the Construction sector as a whole [4] - In comparison, another stock in the Construction sector, Orion Energy Systems, Inc. (OESX), has shown a year-to-date return of 16.4% [4] - Legence belongs to the Engineering - R and D Services industry, which has seen an average gain of 11.3% this year, indicating that LGN is slightly underperforming its industry [6] Group 3: Industry Context - The Engineering - R and D Services industry, which includes Legence, is currently ranked 109 in the Zacks Industry Rank [6] - In contrast, Orion Energy Systems, Inc. is part of the Building Products - Lighting industry, which has a higher rank of 23 and has moved up by 1.2% since the beginning of the year [7]